A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He?

A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He? The passage is a newspaper profile of Senate candidate Bob Hugin and his former role at Celgene. It repeats publicly known facts about drug pricing, FDA warnings, and a 2017 settlement. No new documents, transactions, or undisclosed relationships are revealed, and the only high‑profile actors mentioned (Hugin, Menendez, Christie) are already linked in public discourse. Consequently, it offers minimal actionable investigative leads. Key insights: Bob Hugin was CFO then executive chairman of Celgene, a company that grew from a leprosy drug to a $80 billion pharma firm.; Celgene paid $280 million in 2017 to settle a whistle‑blower lawsuit over off‑label promotion of Revlimid and Thalomid.; The drug Revlimid’s price rose from $6,000 to over $16,000 per month between 2006 and 2017.